Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Market Cap: US$2.5b

Kymera Therapeutics Future Growth

Future criteria checks 2/6

Kymera Therapeutics's earnings are forecast to decline at 6% per annum while its annual revenue is expected to grow at 24.2% per year. EPS is expected to decline by 1.1% per annum. Return on equity is forecast to be -60.7% in 3 years.

Key information

-6.0%

Earnings growth rate

-1.1%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate24.2%
Future return on equity-60.7%
Analyst coverage

Good

Last updated11 Mar 2024

Recent future growth updates

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Recent updates

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces

Aug 15

Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M

Aug 09

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Jul 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics: A First Take

Feb 28

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth

Feb 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth

Earnings and Revenue Growth Forecasts

NasdaqGM:KYMR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202671-279-192-16712
12/31/202572-251-189-16316
12/31/202456-216-180-17317
12/31/202379-147-137-103N/A
9/30/202347-167-174-150N/A
6/30/202352-158-169-153N/A
3/31/202347-159-163-157N/A
12/31/202247-155-156-153N/A
9/30/202246-154-155-152N/A
6/30/202257-139-157-155N/A
3/31/202264-124-148-146N/A
12/31/202173-100-131-129N/A
9/30/202170-79-113-111N/A
6/30/202165-585458N/A
3/31/202149-486977N/A
12/31/202034-557988N/A
9/30/202023-539097N/A
6/30/20209-57-52-47N/A
3/31/20206-52-17-15N/A
12/31/20193-411718N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KYMR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KYMR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KYMR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KYMR's revenue (24.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: KYMR's revenue (24.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KYMR is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.